Three JAK inhibitors—ruxolitinib, upadacitnib (JAK1 inhibitor), and abrocitinib (JAK1 inhibitor)—recently gained FDA approval for atopic dermatitis treatment in the U.S [163]. This evidence concerns the gene JAK1 and atopic eczema.